Fierce Pharma has introduced a weekly Oral GLP-1 Tracker, a new data feature built on analyst notes and IQVIA prescription data. The aim is to provide ongoing visibility into how oral weight-loss drugs are performing in the market.
The tracker will focus on prescription trends and market share shifts as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo compete to become the leading oral GLP-1 option. Both companies are vying for a large patient population seeking convenient weight-loss treatments.
In its first edition, the tracker notes that the holiday period took a toll on prescriptions. No specific figures were provided in the announcement, but the seasonal dip sets a baseline for the weekly series.